Yang Li-li, Wang Miao, Liu Tao, Song Hai-yan, Li Dong-fei, Zheng Pei-yong, Liu Ping, Ji Guang, Ji Guang
Institute of Digestive Diseases, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Zhong Xi Yi Jie He Xue Bao. 2011 Sep;9(9):998-1004. doi: 10.3736/jcim20110911.
To study the effects of Jiangzhi Granule (JZG), a compound traditional Chinese herbal medicine, in regulating liver X receptor α (LXRα) and sterol regulatory element-binding protein-1c (SREBP-1c) expressions in a rat model of non-alcoholic fatty liver disease (NAFLD).
Forty specific pathogen-free Wistar male rats were randomly divided into normal group, untreated group, pioglitazone (PIO) group and JZG group. All rats were fed with high-fat diet (88% normal chow plus 10% lard plus 2% cholesterol) for 4 weeks except for the normal group. After the NAFLD model was established, PIO and JZG were fed to rats in the corresponding groups respectively for another 4 weeks. At the end of the 8th week, liver steatosis level was observed under a light microscope with hematoxylin and eosin (HE) staining; serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities and triacylglycerol (TAG) and free fatty acid (FFA) contents in liver tissues were measured. LXRα and SREBP-1c expressions in liver tissues were determined by real-time polymerase chain reaction and Western blot methods.
Compared with the normal group, there were physiological changes for hepatic steatosis in liver tissues in the untreated group as observed by HE staining. JZG improved serum ALT and AST levels which were significantly increased in the untreated group. Both JZG and PIO improved FFA and TAG levels in liver tissues which were significantly increased in the untreated group. mRNA and protein levels of LXRα and SREBP-1c in the untreated group were higher than those in the normal group, while the treatment of JZG and PIO lowered their expressions.
JZG may regulate fatty acid metabolic disorder by decreasing the levels of LXRα and SREBP-1c.
研究复方中药降脂颗粒（JZG）对非酒精性脂肪性肝病（NAFLD）大鼠模型肝脏X受体α（LXRα）和固醇调节元件结合蛋白-1c（SREBP-1c）表达的影响。
将40只无特定病原体的Wistar雄性大鼠随机分为正常组、未治疗组、吡格列酮（PIO）组和JZG组。除正常组外，所有大鼠均给予高脂饮食（88%普通饲料加10%猪油加2%胆固醇）4周。建立NAFLD模型后，分别给予相应组大鼠PIO和JZG再治疗4周。第8周结束时，用苏木精-伊红（HE）染色在光学显微镜下观察肝脏脂肪变性程度；检测血清丙氨酸氨基转移酶（ALT）和天冬氨酸氨基转移酶（AST）活性以及肝组织中三酰甘油（TAG）和游离脂肪酸（FFA）含量。采用实时聚合酶链反应和蛋白质印迹法测定肝组织中LXRα和SREBP-1c的表达。
HE染色显示，与正常组相比，未治疗组肝组织出现肝脏脂肪变性的生理变化。JZG改善了未治疗组中显著升高的血清ALT和AST水平。JZG和PIO均改善了未治疗组中显著升高的肝组织FFA和TAG水平。未治疗组中LXRα和SREBP-1c的mRNA和蛋白水平高于正常组，而JZG和PIO治疗降低了它们的表达。
JZG可能通过降低LXRα和SREBP-1c水平来调节脂肪酸代谢紊乱。
